SEARCH

SEARCH BY CITATION

References

  • Al Juburi, G., Laverty, A.A., Green, S.A., Phekoo, K.J., Banarsee, R., Okoye, N.V.O., Bell, D. & Majeed, A. (2012) Trends in hospital admissions for sickle cell disease in England, 2001/02–2009/10. Journal of Public Health, 34, 570576.
  • Ballas, S.K. (2008) Meperidine for acute sickle cell pain in the emergency department: revisited controversy. Annals of Emergency Medicine, 51, 217.
  • Ballas, S.K. & Smith, E.D. (1992) Red blood cell changes during the evolution of the sickle cell painful crisis. Blood, 79, 21542163.
  • Ballas, S.K., Bauserman, R.L., McCarthy, W.F., Castro, O.L., Smith, W.R. & Waclawiw, M.A. (2010) Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. Journal of Pain and Symptom Management, 40, 870882.
  • Ballas, S.K., Gupta, K. & Adams-Graves, P. (2012) Sickle cell pain: a critical reappraisal. Blood, 120, 36473656.
  • Barrett, M.J., Cronin, J., Murphy, A., McCoy, S., Hayden, J., an Fhailí, S., Grant, T., Wakai, A., McMahon, C., Walsh, S. & O'Sullivan, R. (2012) Intranasal fentanyl versus intravenous morphine in the emergency department treatment of severe painful sickle cell crises in children: study protocol for a randomised controlled trial. Trials, 13, 74.
  • van Beers, E.J., van Tuijn, C.F., Nieuwkerk, P.T., Friederich, P.W., Vranken, J.H. & Biemond, B.J. (2007) Patient-controlled analgesia versus continuous infusion of morphine during vaso-occlusive crisis in sickle cell disease, a randomized controlled trial. American Journal of Hematology, 82, 955960.
  • Bredenberg, S., Duberg, M., Lennernas, B., Lennernas, H., Pettersson, A., Westerberg, M. & Nystrom, C. (2003) In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. European Journal of Pharmaceutical Sciences, 20, 327334.
  • Buchanan, I.D., Woodward, M. & Reed, G.W. (2005) Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome. Pediatric Blood & Cancer, 45, 716724.
  • Caraceni, A., Pigni, A. & Brunelli, C. (2011) Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliative Medicine, 25, 402409.
  • Christensen, M.L., Wang, W.C., Harris, S., Eades, S.K. & Wilimas, J.A. (1996) Transdermal fentanyl administration in children and adolescents with sickle cell pain crisis. Journal of Pediatric Hematology/oncology, 18, 372376.
  • Dampier, C.D., Smith, W.R., Kim, H.Y., Wager, C.G., Bell, M.C., Minniti, C.P., Keefer, J., Hsu, L., Krishnamurti, L., Mack, A.K., McClish, D., McKinlay, S.M., Miller, S.T., Osunkwo, I., Seaman, P., Telen, M.J. & Weiner, D.L. (2011) Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodes. American Journal of Hematology, 86, E70E73.
  • Darwish, M., Tempero, K., Kirby, M. & Thompson, J. (2005) Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clinical Pharmacokinetics, 44, 12791286.
  • Darwish, M., Kirby, M., Robertson, P. Jr, Tracewell, W. & Jiang, J.G. (2006) Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clinical Therapeutics, 28, 707714.
  • Darwish, M., Kirby, M., Robertson, P. Jr, Tracewell, W. & Jiang, J.G. (2007) Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. Journal of Clinical Pharmacology, 47, 343350.
  • Dietis, N., Rowbotham, D.J. & Lambert, D.G. (2011) Opioid receptor subtypes: fact or artifact? British Journal of Anaesthesia, 107, 818.
  • Dunlop, R.J. & Bennett, K.C. (2006) Pain management for sickle cell disease. Cochrane Database Systematic Review, CD003350.
  • Elander, J., Lusher, J., Bevan, D. & Telfer, P. (2003) Pain management and symptoms of substance dependence among patients with sickle cell disease. Social Science and Medicine, 57, 16831696.
  • Elander, J., Lusher, J., Bevan, D., Telfer, P. & Burton, B. (2004) Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. Journal of Pain and Symptom Management, 27, 156169.
  • Elander, J., Marczewska, M., Amos, R., Thomas, A. & Tangayi, S. (2006) Factors affecting hospital staff judgments about sickle cell disease pain. Journal of Behavioral Medicine, 29, 203214.
  • Hoskin, P.J., Hanks, G.W., Aherne, G.W., Chapman, D., Littleton, P. & Filshie, J. (1989) The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. British Journal of Clinical Pharmacology, 27, 499505.
  • Jacobson, S.J., Kopecky, E.A., Joshi, P. & Babul, N. (1997) Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet, 350, 13581361.
  • Kendall, J.M., Reeves, B.C. & Latter, V.S. (2001) Multicentre randomised controlled trial of nasal diamorphine for analgesia in children and teenagers with clinical fractures. BMJ, 322, 261265.
  • Kidd, S., Brennan, S., Stephen, R., Minns, R. & Beattie, T. (2009) Comparison of morphine concentration-time profiles following intravenous and intranasal diamorphine in children. Archives of Disease in Childhood, 94, 974978.
  • Kopecky, E.A., Jacobson, S., Joshi, P. & Koren, G. (2004) Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease. Clinical Pharmacology and Therapeutics, 75, 140146.
  • Lahoz, C., Challands, J., Morrison, I., Newell, H., John, Y. & Telfer, P. (2007) Evaluation of an analgesia regime with intranasal diamorphine and oral morphine for acute sickle crisis pain in children. British Journal of Haematology, 137(Suppl. 1), p. 82, abstract 241.
  • Lennernas, B., Hedner, T., Holmberg, M., Bredenberg, S., Nystrom, C. & Lennernas, H. (2005) Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. British Journal of Clinical Pharmacology, 59, 249253.
  • Maxwell, K., Streetly, A. & Bevan, D. (1999) Experiences of hospital care and treatment seeking for pain from sickle cell disease: qualitative study. BMJ, 318, 15851590.
  • Melzer-Lange, M.D., Walsh-Kelly, C.M., Lea, G., Hillery, C.A. & Scott, J.P. (2004) Patient-controlled analgesia for sickle cell pain crisis in a pediatric emergency department. Pediatric Emergency Care, 20, 24.
  • MHRA (2013) Press release: MHRA confirms codeine not to be used in children under 12 years old. http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON287048 [Accessed 23 November 2013].
  • Miller, S.T., Kim, H.Y., Weiner, D., Wager, C.G., Gallagher, D., Styles, L. & Dampier, C.D. (2012) Inpatient management of sickle cell pain: a ‘snapshot’ of current practice. American Journal of Hematology, 87, 333336.
  • NCEPOD (2008) Sickle: A sickle crisis? http://www.ncepod.org.uk/2008sc.htm [Accessed 23 November 2013].
  • NHS Sickle Cell and Thalassaemia Screening Programmes (2010) Sickle Cell Disease in Childhood. Standards and Guidelines for Clinical Care. http://sct.screening.nhs.uk [Accessed 23 November 2013].
  • NICE (2012) Sickle cell acute painful episode: Management of an acute painful sickle cell episode in hospital. NICE Clinical Guideline 143. http://guidance.nice.org.uk/CG143 [Accessed 23 November 2013].
  • Olujohungbe, A., Bennett, L., Chapman, C., Davis, B., Howard, J., Ryan, K., Pancham, S. & Yardumian, A. (2008) Standards for the Clinical Care of Adults with Sickle Cell Disease in the UK. http://sct.screening.nhs.uk/getdata.php?id=10991 [Accessed 23 November 2013].
  • Pathan, H. & Williams, J. (2012) Basic opioid pharmacology: an update. British Journal of Pain, 6, 1116.
  • Peters-Lawrence, M.H., Bell, M.C., Hsu, L.L., Osunkwo, I., Seaman, P., Blackwood, M., Guillaume, E., Bellevue, R., Krishnamurti, L., Smith, W.R., Dampier, C.D. & Minniti, C.P. (2012) Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial. Contemporary Clinical Trials, 33, 291297.
  • Rauck, R.L., Tark, M., Reyes, E., Hayes, T.G., Bartkowiak, A.J., Hassman, D., Nalamachu, S., Derrick, R. & Howell, J. (2009) Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Current Medical Research and Opinion, 25, 28772885.
  • Rees, D.C., Olujohungbe, A.D., Parker, N.E., Stephens, A.D., Telfer, P. & Wright, J. (2003) Guidelines for the management of the acute painful crisis in sickle cell disease. British Journal of Haematology, 120, 744752.
  • Streetly, A., Latinovic, R., Hall, K. & Henthorn, J. (2009) Implementation of universal newborn bloodspot screening for sickle cell disease and other clinically significant haemoglobinopathies in England: screening results for 2005–7. Journal of Clinical Pathology, 62, 2630.
  • Streisand, J.B., Busch, M.A., Egan, T.D., Smith, B.G., Gay, M. & Pace, N.L. (1998) Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology, 88, 305309.
  • Telfer, P., Criddle, J., Sandell, J., Davies, F., Morrison, I. & Challands, J. (2009) Intranasal diamorphine for acute sickle cell pain. Archives of Disease in Childhood, 94, 979980.
  • Tremlett, M.R. (2013) Wither codeine? Paediatric Anaesthesia, 23, 677683.
  • Williams, S., Bottle, A., Rogers, R. & Aylin, P. (2005) “Frequent flier” patients. BMJ, 330, 869.
  • Wilson, J.A., Kendall, J.M. & Cornelius, P. (1997) Intranasal diamorphine for paediatric analgesia: assessment of safety and efficacy. Journal of Accident and Emergency Medicine, 14, 7072.